it'll be interesting as the offer wasn't underwritten .. so they are not obliged to take up the offer at 17 cents.
either way the objective of the cap raise is to get funding for the business to continue its operations... the secondary market action in the short term is somewhat irrelevant to the business, but may as you suggest result in heigtened volatility, which is somewhat to be expected anyway after a cap raise (float has increased significantly), and as per usual it will take material progress to push the price above A$0.17c and there are a number of sources of that.. with the ongoing CLTX trial progress the most likely.
ASCO is coing up in the first week of June (June 3 - 7 in Chicago) .. and SNO in November (17-20 in Tampa, Florida).
i suspect a deep dive into cohort 2 at ASCO, and maybe if we are luck a sneak peak at data for cohort 3.
But for SNO, we should get a full read out for cohort 3 and if lucky we get a sneak peak at cohort 4 as well.
CHM Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)